Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

New York, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Analysis Demonstrates 22+ Key Companies at the Horizon Expected to Transform the Treatment...
May 07, 2019 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
October 22, 2018 08:45 ET | Source: Kura Oncology, Inc.

Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
September 26, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
August 30, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at H.C. Wainwright Global Investment Conference

SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
August 07, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
August 06, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update

– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
June 28, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock

SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 20, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
June 14, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at JMP Securities Life Sciences Conference

SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...

Next Page keyboard_arrow_right